2021.11.10
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
I-Mab today announced that it has entered into a strategic collaboration agreement with Jumpcan Pharmaceutical Group for the development, manufacturing and commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China.